Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1789)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3712)
  2. Department of Medicine (3681)
  3. Hematologic Malignancies, Division of (3677)
  4. GSK Faculty (1782)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1377)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (501)
  4. Jae Park (383)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (95)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia
    Review

    Patel, A. A.; Rampal, R. K.
    Haematologica (2025)

    Fulltext@MSK | Save
  • Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: A report from the Beat AML clinical trial
    Research Letter

    Hoff, F. W.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H. Jr; Baer, M. R.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma
    Journal Article

    Luna, A.; Devlin, S. M.; Rejeski, K.; Flynn, J. R.; Corona, M.; Luttwak, E.; Rivas-Delgado, A.; Landego, I.; Cassanello, G.; Gomez-Llobell, M.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
    Research Letter

    Goyal, G.; Reiner, A. S.; Bossert, D.; Sigler, A. M.; Lacouture, M. E.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; Diamond, E. L.
    Blood (2025)

    Fulltext@MSK | Save
  • Risk factors associated with sub-optimal outcomes and hematotoxicity following obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Meeting Abstract

    Sandhu, K. S.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Abedi, M.; Shah, B.; Bishop, M. R.; Deangelo, D. J.; Brugger, W.; Shang, J.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and-7
    Meeting Abstract

    Kunimoto, H.; Honma, D.; Tsutsumi, S.; Sakuma, T.; Ohashi, T.; Teranaka, H.; Ikeda, J.; Toya, T.; Harada, Y.; Doki, N.; more...
    Cancer Science (2025)

    Fulltext@MSK | Save
  • Enhancing the persistence and anti-tumor efficacy of CAR-T and CAR-NK cells through genetic disruption of death receptors
    Meeting Abstract

    Cohen, T. D.; Yi, F.; Zumbo, P.; Etilib, R.; Arkin, H.; Gormally, M.; Hackett, C. S.; Kropp, K.; Etxeberria, I.; Chandran, S. S.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Selinexor plus ruxolitinib in JAK inhibitor treatment-naìˆve myelofibrosis: SENTRY Phase 3 study design
    Journal Article

    Mascarenhas, J.; Maher, K.; Rampal, R.; Bose, P.; Podoltsev, N.; Hong, J.; Chai, Y.; Kye, S.; Method, M.; Harrison, C.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • How I treat acute myeloid leukemia with differentiation therapy
    Review

    Issa, G. C.; Stein, E. M.; DiNardo, C. D.
    Blood (2025)

    Fulltext@MSK | Save